Caroline Dutriaux
A5055627811- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Immunotherapy and Immune Responses
- Hedgehog Signaling Pathway Studies
- Cancer and Skin Lesions
- Brain Metastases and Treatment
- Computational Drug Discovery Methods
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Polyomavirus and related diseases
- Synthesis of Tetrazole Derivatives
- Click Chemistry and Applications
- Ocular Oncology and Treatments
- Synthesis and biological activity
- Multiple Myeloma Research and Treatments
- Cancer Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Health Systems, Economic Evaluations, Quality of Life
- Radiopharmaceutical Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
Université de Bordeaux
2015-2025
Inserm
2019-2025
Hôpital Saint-André
2015-2024
Centre Hospitalier Universitaire de Bordeaux
2015-2024
Bordeaux Population Health
2018-2024
Princess Alexandra Hospital
2019-2024
Melanoma Institute Australia
2019-2024
The University of Queensland
2024
The University of Sydney
2019-2024
Royal North Shore Hospital
2024
Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients ipilimumab-refractory metastatic melanoma. The use nivolumab previously untreated advanced melanoma has not been tested controlled study.We randomly assigned 418 who had without BRAF mutation to receive (at dose mg per kilogram body weight every 2 weeks and dacarbazine-matched placebo weeks) or dacarbazine 1000 square meter body-surface area nivolumab-matched weeks)....
The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset resistance observed inhibitors alone. This randomized phase 3 study evaluated combination inhibitor vemurafenib cobimetinib.We randomly assigned 495 previously untreated unresectable locally advanced metastatic V600 mutation-positive receive cobimetinib (combination group) placebo (control group). primary end point was investigator-assessed...
Combination therapy with the BRAF inhibitor dabrafenib plus MEK trametinib improved survival in patients advanced melanoma V600 mutations. We sought to determine whether adjuvant would improve outcomes resected, stage III mutations.In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 completely V600E or V600K mutations receive oral at a dose of 150 mg twice daily 2 once (combination therapy, 438 patients) two matched placebo tablets (432 for 12 months. The...
In the previously reported primary analysis of this phase 3 trial, 12 months adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo patients with resected stage III melanoma BRAF V600E or V600K mutations. To confirm stability benefit, longer-term data were needed.
This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors.To compare the 3-year survival nivolumab vs that dacarbazine previously untreated melanoma.This of a randomized phase 3 trial analyzed overall data from randomized, controlled, double-blind CheckMate 066 clinical trial. For this ongoing, multicenter academic institution trial, were enrolled January 2013 through...
Objectives To evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well correlation with tumour response. Methods This was a single-centre prospective observational study including all cancer ICIs. The occurrence irAEs response assessed on regular basis. Patients who experienced musculoskeletal symptoms were referred to department rheumatology for clinical evaluation management. Results From...
BackgroundThe SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog pathway inhibitor demonstrating clinical benefit advanced basal cell carcinoma (BCC)—in a patient population representative practice. Primary analysis data are presented.Patients methodsPatients with locally or metastatic BCC received oral vismodegib 150 mg/d until progressive disease, unacceptable toxicity, withdrawal. objective was...
Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We present an updated RFS analysis on the basis of extended study follow-up and a cure-rate model to estimate fraction expected remain relapse free long term. Methods In this phase trial, were randomly assigned 12 months adjuvant dabrafenib...
The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.In this multicenter, double-blind, phase III study, 418 untreated, unresectable, stage III/IV, melanoma were randomly assigned 1:1 to receive 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m2 weeks. primary end point was overall survival (OS), and secondary points included progression-free (PFS),...
Abstract Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall (OS) with addition of cobimetinib to vemurafenib compared in patients previously untreated BRAFV600 mutation–positive advanced melanoma. We report long-term follow-up coBRIM, at least 5 years since the last patient was randomized. Patients Methods: Eligible were 1:1 receive either oral (60 mg once daily on days 1–21 each 28-day cycle) or placebo combination...
Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors targeted therapy may improve treatment outcomes in patients BRAF V600-mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, antibody, (sparta-DabTram), versus placebo (placebo-DabTram)...
Abstract Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients randomized 2:1 (stratified by tumor category) nivolumab 480 mg or placebo every 4 weeks for 12 months. primary endpoint was investigator-assessed recurrence-free survival (RFS). Secondary endpoints included distant metastasis-free (DMFS) and safety. At 7.8 months of minimum follow-up, significantly improved RFS...
The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free than placebo among patients
As gut microbiota composition is an important determinant of response to immune checkpoint inhibitors (ICIs), we examined the effect various co-medications known for their interaction with microbiota, when given at ICI initiation.We identified patients advanced cancer treated between May 2015 and September 2017 in our institution. Co-medications within 1 month before or after first administration were reviewed from medical records. Survival data analysed univariable Cox regression, combined...
BackgroundDual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated grade III pyrexia or photosensitivity depending on combination used. The objective this study was to fully describe adverse events from COLUMBUS evaluating most recent encorafenib+binimetinib.Patients methodsPatients locally advanced, unresectable were randomised receive...